

R E M A R K S

The above changes in the claims merely place this national phase application in the same condition as it was during the international phase, with the multiple dependences being removed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

YOUNG & THOMPSON

By

Thomas W. Perkins
Attorney for Applicants
Registration No. 33,027
Customer No. 00466
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

August 3, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claim have been amended as follows:

3. (Amended) Cell composition according to ~~anyone of claims 1—or 2~~, containing T lymphocytes, preferably in a ratio of about 10 to 60% expressed with respect to the total number of cells.

4. (Amended) Cell composition according to ~~anyone of claims 1 to 3~~2, wherein the progenitor cells contain from about 0,1 % to about 20 % of CD34⁺ stem cells, expressed with respect to the total number of progenitor cells.

6. (Amended) Cell composition according to ~~anyone of claims 1 to 5~~2, wherein the macrophages, myeloid cells and the lymphocytes if present, are included in/or generated from blood mononuclear cells.

10. (Amended) Process according to ~~anyone of claims 8—or 9~~, comprising an additional step of macrophage activation, at the end of the coculture, for instance by addition of γ -interferon or muramyl peptides.

11. (Amended) Process according to ~~anyone of claims 6 to 10~~7, comprising an additional step of concentration of the cells obtained at the end of the coculture, and resuspension in a vehicle suitable for administration to a patient.

13. (Amended) Cell composition such as obtained according to the process of ~~anyone of claims 7 to 12~~.

14. (Amended) Pharmaceutical composition containing, as active substance, ~~a cellular~~the cell composition according to ~~anyone of claims 1 to 6 or 13~~.

15. (Amended) Cell composition according to ~~anyone of claims 1 to 6 or 13~~, characterized by the fact that it is derived from and/or included in a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0,1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells,
- from about 0,1 to about 20% of stem cells.

16. (Amended) Use of a cell composition according to ~~anyone of claims 1 to 6 or 13~~, for the preparation of drugs, for the restoration of hematopoiesis in an aplastic patient and/or the protection of patients against infectious diseases or against residual tumors.